Editorial to the Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF Japan): One‐year safety and effectiveness analyses

Detalles Bibliográficos
Autores principales: Nagashima, Koichi, Okumura, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279980/
https://www.ncbi.nlm.nih.gov/pubmed/32528564
http://dx.doi.org/10.1002/joa3.12340
_version_ 1783543658865229824
author Nagashima, Koichi
Okumura, Yasuo
author_facet Nagashima, Koichi
Okumura, Yasuo
author_sort Nagashima, Koichi
collection PubMed
description
format Online
Article
Text
id pubmed-7279980
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72799802020-06-10 Editorial to the Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF Japan): One‐year safety and effectiveness analyses Nagashima, Koichi Okumura, Yasuo J Arrhythm Editorial John Wiley and Sons Inc. 2020-04-15 /pmc/articles/PMC7279980/ /pubmed/32528564 http://dx.doi.org/10.1002/joa3.12340 Text en © 2020 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Editorial
Nagashima, Koichi
Okumura, Yasuo
Editorial to the Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF Japan): One‐year safety and effectiveness analyses
title Editorial to the Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF Japan): One‐year safety and effectiveness analyses
title_full Editorial to the Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF Japan): One‐year safety and effectiveness analyses
title_fullStr Editorial to the Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF Japan): One‐year safety and effectiveness analyses
title_full_unstemmed Editorial to the Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF Japan): One‐year safety and effectiveness analyses
title_short Editorial to the Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF Japan): One‐year safety and effectiveness analyses
title_sort editorial to the postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (etna‐af japan): one‐year safety and effectiveness analyses
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279980/
https://www.ncbi.nlm.nih.gov/pubmed/32528564
http://dx.doi.org/10.1002/joa3.12340
work_keys_str_mv AT nagashimakoichi editorialtothepostmarketingsurveillanceontheclinicaluseofedoxabaninpatientswithnonvalvularatrialfibrillationetnaafjapanoneyearsafetyandeffectivenessanalyses
AT okumurayasuo editorialtothepostmarketingsurveillanceontheclinicaluseofedoxabaninpatientswithnonvalvularatrialfibrillationetnaafjapanoneyearsafetyandeffectivenessanalyses

Ejemplares similares